Dermira (DERM) was Downgraded to a Hold Rating at Needham

By Ryan Adsit

In a report released today, Serge Belanger from Needham downgraded Dermira (DERMResearch Report) to Hold. The company’s shares closed last Monday at $18.71, close to its 52-week high of $19.48.

According to TipRanks.com, Belanger is a 4-star analyst with an average return of 9.3% and a 50.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Dermira is a Moderate Buy with an average price target of $16.90, a -10.1% downside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Hold rating on the stock with a $18.80 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.48 and a one-year low of $5.25. Currently, Dermira has an average volume of 2.27M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis and atopic dermatitis.